23 results on '"Bollet MA"'
Search Results
2. Abstract P5-14-18: Extended Pure Ductal Carcinoma In Situ of the Breast on Preoperative Biopsies. Prognostic Factors for Infiltrating Carcinoma and Lymph Node Involvement
- Author
-
Guillot, E, primary, Goetgheluck, J, additional, Couturaud, B, additional, Fitoussi, A, additional, Salmon, RJ, additional, Malhaire, C, additional, Falcou, M-C, additional, Mosseri, V, additional, Sastre, X, additional, Bollet, MA, additional, and Reyal, F., additional
- Published
- 2010
- Full Text
- View/download PDF
3. Technique alternatives for breast radiation oncology: Conventional radiation therapy to tomotherapy
- Author
-
Fournier-Bidoz, N, primary, Kirova, Y, additional, Campana, F, additional, El Barouky, J, additional, Zefkili, S, additional, Dendale, R, additional, Bollet, MA, additional, Mazal, A, additional, and Fourquet, A, additional
- Published
- 2009
- Full Text
- View/download PDF
4. Preliminary result of a mono-institutional, prospective study of skin and cardiac toxicities in breast cancer patients treated by concurrent adjuvant trastuzumab and radiotherapy involving in most cases the internal mammary chain.
- Author
-
Bollet, MA, primary, Kirova, YM, additional, Granger, B, additional, Caussa, L, additional, Savignoni, A, additional, Pierga, J, additional, Campana, F, additional, Dendale, R, additional, and Fourquet, A, additional
- Published
- 2009
- Full Text
- View/download PDF
5. Evaluating tumour response to primary radiochemotherapy in breast cancer patients: what role for breast magnetic resonance imaging?
- Author
-
Thibault, F, primary, Bollet, MA, additional, Tardivon, A, additional, Malhaire, C, additional, and Zemmour-Elfersi, G, additional
- Published
- 2008
- Full Text
- View/download PDF
6. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis.
- Author
-
Des Guetz G, Landre T, Bollet MA, Mathonnet M, and Quéro L
- Abstract
Background: Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still unclear., Methods: To identify clinical trials combining oxaliplatin in preoperative CRT or perioperative chemotherapy for LARC published until March 2021, we searched PubMed and the Cochrane Library. We also searched for relevant ASCO conference abstracts. The primary endpoint was disease-free survival (DFS). Data were extracted from every study to perform a meta-analysis using Review Manager (version 5.3)., Results: A total of seven randomized clinical trials (ACCORD-12, CARO-AIO-04, FOWARC, JIAO, NSABP, PETACC-6, and STAR-01) with 5782 stage II or III rectal cancer patients were analyzed, including 2727 patients with OXP + 5FU regimen and 3055 patients with 5FU alone. Compared with the 5FU alone group, the OXP + 5FU regimen improved DFS (HR = 0.90, 95% CI: 0.81-0.99, p = 0.03) and pathologic complete response (pCR) (OR = 1.21, 95% CI: 1.07-1.37, p = 0.002). Patients treated with the OXP + 5FU regimen had significantly less metastatic progression (OR = 0.79; 95% CI, 0.67 to 0.94; p = 0.007). Considering adverse events (AEs), there was more grade 3-4 diarrhea with OXP + 5FU (OR = 2.41, 95% CI: 1.74-3.32, p < 0.00001). However, there were no significant differences grade 3-4 hematologic AEs (OR = 1.16, 95% CI: 0.87-1.57, p = 0.31)., Conclusions: Our meta-analysis with long-term results from the randomized studies showed a benefit of the addition of OXP + 5FU regiment in terms of DFS, metastatic progression, and pCR rate that did not translate to improved OS.
- Published
- 2021
- Full Text
- View/download PDF
7. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.
- Author
-
Guillot E, Vaysse C, Goetgeluck J, Falcou MC, Couturaud B, Fitoussi A, Fourchotte V, Laki F, Malhaire C, Sigal-Zafrani B, Sastre-Garau X, Bollet MA, Mosseri V, and Reyal F
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms surgery, Carcinoma, Intraductal, Noninfiltrating surgery, Female, Humans, Lymphatic Metastasis, Mammaplasty methods, Middle Aged, Risk Factors, Breast Neoplasms pathology, Carcinoma, Intraductal, Noninfiltrating secondary, Lymph Nodes pathology
- Abstract
Aim: To identify predictors for infiltrating carcinoma and lymph node involvement, before immediate breast reconstructive surgery, in patients with an initial diagnosis of extensive pure ductal carcinoma in situ of the breast (DCIS)., Patients and Methods: Between January 2000 and December 2009, 241 patients with pure extensive DCIS in preoperative biopsy had underwent mastectomy. Axillary staging (sentinel node and/or axillary dissection) was performed in 92% (n = 221) of patients. Patients with micro-invasive lesions at initial diagnosis, recurrence or contralateral breast cancer were excluded., Results: Respectively 14% and 21% of patients had a final diagnosis of micro-invasive carcinoma (MIC) and invasive ductal carcinoma (IDC). Univariate analysis showed that the following variables at diagnosis were significantly correlated with the presence of either MIC or IDC in the mastectomy specimen: palpable tumor (p = 0.002), high grade DCIS (p = 0.002) and detection of an opacity by mammography (p = 0.019). Axillary lymph node (ALN) involvement was reported in 9% of patients. Univariate analysis suggested that a body mass index higher than 25 (p = 0.007), a palpable tumor (p = 0.012) and the detection of an opacity by mammography (p = 0.044) were associated with an increased rate of ALN involvement., Conclusion: Skin-sparing mastectomy and immediate breast reconstruction (IBRS) has become increasingly popular, especially for patients with extended DCIS of the breast. This study confirmed that extended DCIS is associated with a substantial risk of finding MIC or IDC on the surgical specimen but also ALN involvement. Adjuvant systemic treatment and/or radiotherapy could be indicated for some of these patients after the surgery. Patients should be informed of the rate of 1) complications associated to IBRS that will potentially delay the introduction of systemic or local therapy 2) complications associated to radiotherapy after IBRS., (Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
8. Adjuvant radiotherapy in the management of axillary node negative invasive breast cancer: a qualitative systematic review.
- Author
-
Bourgier C, Aimard L, Bodez V, Bollet MA, Cutuli B, Franck D, Hennequin C, Kirova YM, and Azria D
- Subjects
- Axilla, Breast Neoplasms pathology, Breast Neoplasms surgery, Female, Humans, Lymphatic Metastasis, Mastectomy, Segmental, Neoplasm Invasiveness, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Adjuvant, Tumor Burden, Breast Neoplasms radiotherapy, Lymph Nodes pathology
- Abstract
Purpose: To actualize and to detail guidelines used in technical radiotherapy and indications for innovative radiation technologies in early axillary node negative breast cancer (BC)., Methods: Dosimetric and treatment planning studies, phase II and III trials, systematic reviews and retrospective studies were all searched (Medline(®) database). Their quality and clinical relevance were also checked against validated checklists. A level of evidence was associated for each result., Results: A total of 75 references were included. Adjuvant BC radiotherapy (50Gy/25 fractions/5 weeks followed by a tumor boost of 16Gy/8 fractions) is still the standard of care. Overall treatment time could be shortened for patients who present with low local relapse risk BC by using either hypofractionated whole breast irradiation; or accelerated partial breast irradiation. BC IMRT is not used in current practice., Conclusion: Our group aimed to provide guidelines for technical and clinical applications of innovative BC radiation technologies., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
9. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.
- Author
-
Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, Fourchotte V, Laki F, Alran S, Asselain B, Vincent-Salomon A, Sigal-Zafrani B, and Sastre-Garau X
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Breast Neoplasms therapy, Combined Modality Therapy, Female, Humans, Middle Aged, Mitotic Index, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Retrospective Studies, Breast Neoplasms metabolism, Ki-67 Antigen metabolism
- Abstract
Background: Molecular signatures may become of use in clinical practice to assess the prognosis of breast cancers. However, although international consensus conferences sustain the use of these new markers in the near future, concerns remain about their degree of discordance and cost-effectiveness in different international settings. The present study aims to validate Ki67 as prognostic factor in a large cohort of early-stage (pT1-pT2, pN0) breast cancer patients., Methods: 456 patients treated in 1995-1996 were identified in the Institut Curie database. Ki67 (MIB1) was retrospectively assessed by immunohistochemistry for all cases. The prognostic value of this index was compared to that of histological grade (HG), Estrogen receptor (ER) and HER2 status. Distant disease free interval, loco-regional recurrence, time-lapse from first metastatic diagnosis to death were analyzed., Results: All 456 patients were treated by lumpectomy plus axillary dissection and radiotherapy. 27 patients (5.9%) received systemic treatment. Tumors were classified as HG1 in 35%, HG2 in 42% and HG3 in 23% of cases. ER was expressed in 86% of the tumors, HER2 in 5% and 14% were triple negative. The median follow-up was 151 [5-191] months. Distant and loco-regional disease recurrences were observed in 16% and 18%, respectively. High (>20%) Ki67 rate [HR = 3 (1.8-4.8), p<10e-06] and HG3 [HR = 4.4 (2.2-8.6), p = 0.00002] were associated with an increased rate of distant relapse. In multivariate analysis, the Ki67 remained the only significant prognostic factor in the subgroups of ER positive HER2 negative [HR = 2.6 (1.5-4.6), p = 0.0006] and ER positive HER2 negative HG2 tumors [HR = 2.2 (1.01-4.8), p = 0.04]., Conclusions: We validate the prognosis value of the Ki67 rate in small size node negative breast cancer. We conclude that Ki67 is a potential cost-effective decision marker for adjuvant therapy in early-stage HG2, pT1-pT2, pN0, breast cancers.
- Published
- 2013
- Full Text
- View/download PDF
10. Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.
- Author
-
Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, De Cremoux P, Fourquet A, and Kirova YM
- Abstract
Aim: To retrospectively assess the acute and long-term toxicity using aromatase inhibitors (AI) therapy concurrently with hypofractionated radiotherapy (HFRT) in breast cancer patients., Methods: From November 1999 to October 2007, 66 patients were treated with breast HFRT and concurrent AI. In 63 patients (95.5%), HFRT delivered a total dose of 32.5 Gy to the whole breast within 5 wk (five fractions, one fraction per week). Other fractionations were chosen in three patients for the patients' personal convenience. A subsequent boost to the tumor bed was delivered in 35 patients (53.0%). Acute toxicities were scored according to the Common Toxicity Criteria for Adverse Events v3. Late toxicity was defined as any toxicity occurring more than 6 mo after completion of HFRT and was scored according to the Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic scale., Results: At the end of the HFRT course, 19 patients (28.8%) had no irradiation-related toxicity. Acute grade 1-2 epithelitis was observed in 46 patients (69.7%). One grade 3 toxicity (1.5%) was observed. With a median follow-up of 34 mo (range: 12-94 mo), 31 patients (47%) had no toxicity, and 35 patients (53%) presented with grade 1-2 fibrosis. No grade 3 or greater delayed toxicity was observed., Conclusion: We found that AI was well tolerated when given concurrently with HFRT. All toxicities were mild to moderate, and no treatment disruption was necessary. Further prospective assessment is warranted.
- Published
- 2012
- Full Text
- View/download PDF
11. Search for a gene expression signature of breast cancer local recurrence in young women.
- Author
-
Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, and van de Vijver MJ
- Subjects
- Adult, Female, Humans, Prognosis, Recurrence, Validation Studies as Topic, Breast Neoplasms genetics, Gene Expression Profiling
- Abstract
Purpose: A gene expression signature, predictive for local recurrence after breast-conserving treatment, has previously been identified from a series of 165 young patients with breast cancer. We evaluated this signature on both another platform and an independent series, compared its performance with other published gene-sets, and investigated the gene expression profile of a larger data set., Experimental Design: Gene expression tumor profiles were obtained on 148 of the initial 165 Dutch patients and on an independent validation series of 195 French patients. Both unsupervised and supervised classifications were used to study the gene expression profile of the 343 breast cancers and to identify subgroups that differ for their risk of local recurrence., Results: The previous local recurrence signature was validated across platforms. However, when applied to the French patients, the signature did not reproduce its reported performance and did not better classify the patients than other published gene sets. Hierarchical clustering of all 343 breast cancers did not show any grouping reflecting local recurrence status. Genes related to proliferation were found differentially expressed between patients with or without local recurrence only in triple-negative tumors. Supervised classification revealed no significant gene set predictive for local recurrence or able to outperform classification based on clinical variables., Conclusions: Although the previously identified local recurrence signature was robust on another platform, we were neither able to validate it on an independent data set, nor able to define a strong gene expression classifier for local recurrence using a larger data set. We conclude that there are no significant differences in gene expression pattern in tumors from patients with and without local recurrence after breast-conserving treatment.
- Published
- 2012
- Full Text
- View/download PDF
12. Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
- Author
-
Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, and Sastre-Garau X
- Subjects
- Adult, Aged, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Carcinoma drug therapy, Carcinoma mortality, Female, Follow-Up Studies, Humans, Immunophenotyping, Kaplan-Meier Estimate, Ki-67 Antigen genetics, Ki-67 Antigen metabolism, Middle Aged, Mitotic Index, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Transcriptome, Breast Neoplasms genetics, Breast Neoplasms pathology, Carcinoma genetics, Carcinoma pathology
- Abstract
Background: Genomic grade (GG) is a 97-gene signature which improves the accuracy and prognostic value of histological grade (HG) in invasive breast carcinoma. Since most of the genes included in the GG are involved in cell proliferation, we performed a retrospective study to compare the prognostic value of GG, Mitotic Index and Ki67 score., Methods: A series of 163 consecutive breast cancers was retained (pT1-2, pN0, pM0, 10-yr follow-up). GG was computed using MapQuant Dx(R)., Results: GG was low (GG-1) in 48%, high (GG-3) in 31% and equivocal in 21% of cases. For HG-2 tumors, 50% were classified as GG-1, 18% as GG-3 whereas 31% remained equivocal. In a subgroup of 132 ER+/HER2- tumors GG was the most significant prognostic factor in multivariate Cox regression analysis adjusted for age and tumor size (HR = 5.23, p = 0.02)., Conclusions: In a reference comprehensive cancer center setting, compared to histological grade, GG added significant information on cell proliferation in breast cancers. In patients with HG-2 carcinoma, applying the GG to guide the treatment scheme could lead to a reduction in adjuvant therapy prescription. However, based on the results observed and considering (i) the relatively close prognostic values of GG and Ki67, (ii) the reclassification of about 30% of HG-2 tumors as Equivocal GG and (iii) the economical and technical requirements of the MapQuant micro-array GG test, the availability in the near future of a PCR-based Genomic Grade test with improved performances may lead to an introduction in clinical routine of this test for histological grade 2, ER positive, HER2 negative breast carcinoma.
- Published
- 2012
- Full Text
- View/download PDF
13. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.
- Author
-
Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, and De Rycke Y
- Subjects
- Aged, Female, Humans, Logistic Models, Middle Aged, Multivariate Analysis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Sentinel Lymph Node Biopsy, Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinoma metabolism, Carcinoma pathology
- Abstract
Introduction: Several authors have underscored a strong relation between the molecular subtypes and the axillary status of breast cancer patients. The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy., Materials and Methods: Our dataset consisted of a total number of 2654 early-stage breast cancer patients. Patients treated at first by conservative breast surgery plus sentinel node biopsies were selected. A multivariate logistic regression model was trained and validated. Interaction covariate between ER and HER2 markers was a forced input of this model. The performance of the multivariate model in the training and the two validation sets was analyzed in terms of discrimination and calibration. Probability of axillary metastasis was detailed for each molecular subtype., Results: The interaction covariate between ER and HER2 status was a stronger predictor (p = 0.0031) of positive sentinel node biopsy than the ER status by itself (p = 0.016). A multivariate model to determine the probability of sentinel node positivity was defined with the following variables; tumour size, lympho-vascular invasion, molecular subtypes and age at diagnosis. This model showed similar results in terms of discrimination (AUC = 0.72/0.73/0.72) and calibration (HL p = 0.28/0.05/0.11) in the training and validation sets. The interaction between molecular subtypes, tumour size and sentinel nodes status was approximated., Discussion: We showed that biologically-driven analyses are able to build new models with higher performance in terms of breast cancer axillary status prediction. The molecular subtype classification strongly interacts with the axillary and distant metastasis process.
- Published
- 2011
- Full Text
- View/download PDF
14. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
- Author
-
Mégnin-Chanet F, Bollet MA, and Hall J
- Subjects
- Animals, Antineoplastic Agents pharmacology, Enzyme Inhibitors pharmacology, Humans, Antineoplastic Agents therapeutic use, Enzyme Inhibitors therapeutic use, Neoplasms drug therapy, Neoplasms enzymology, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases metabolism
- Abstract
Poly(ADP-ribosyl)ation is a ubiquitous protein modification found in mammalian cells that modulates many cellular responses, including DNA repair. The poly(ADP-ribose) polymerase (PARP) family catalyze the formation and addition onto proteins of negatively charged ADP-ribose polymers synthesized from NAD(+). The absence of PARP-1 and PARP-2, both of which are activated by DNA damage, results in hypersensitivity to ionizing radiation and alkylating agents. PARP inhibitors that compete with NAD(+) at the enzyme's activity site are effective chemo- and radiopotentiation agents and, in BRCA-deficient tumors, can be used as single-agent therapies acting through the principle of synthetic lethality. Through extensive drug-development programs, third-generation inhibitors have now entered clinical trials and are showing great promise. However, both PARP-1 and PARP-2 are not only involved in DNA repair but also in transcription regulation, chromatin modification, and cellular homeostasis. The impact on these processes of PARP inhibition on long-term therapeutic responses needs to be investigated.
- Published
- 2010
- Full Text
- View/download PDF
15. The impact of the loco-regional treatment in elderly breast cancer patients: hypo-fractionated exclusive radiotherapy, single institution long-term results.
- Author
-
Chargari C, Kirova YM, Laki F, Savignoni A, Dorval T, Dendale R, Bollet MA, Fourquet A, and Campana F
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast mortality, Carcinoma, Lobular drug therapy, Carcinoma, Lobular mortality, Female, Humans, Kaplan-Meier Estimate, Neoadjuvant Therapy, Proportional Hazards Models, Radiotherapy, High-Energy adverse effects, Retrospective Studies, Treatment Outcome, Breast Neoplasms radiotherapy, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Lobular radiotherapy, Dose Fractionation, Radiation, Radiotherapy, High-Energy methods
- Abstract
Purpose: To assess the efficacy of exclusive hypo-fractionated radiotherapy (HFRT) without previous breast-conserving surgery (BCS) in elderly women., Materials and Methods: From 1995 to 1999, we have treated with breast-conserving treatment 396 patients older than 70 years with early-stage breast cancer (T1,T2 tumours) at the Institut Curie, Paris, France. Seventy-nine consecutive elderly non-metastatic patients treated for early breast cancer have been treated with HFRT. Of them, 50 underwent BCS followed by HFRT of 32.5 Gy/5 fractions/5 weeks, and 29 patients (presented with different co-morbidities, inoperable or patients' refusal, and/or transportation problems) received the same HFRT schedule followed by a 13 Gy boost (two fractions of 6.5 Gy) as exclusive radiotherapy treatment. This population of 29 patients has been studied. In case of hormonal positive status, hormonal therapy was also proposed to the patients., Results: There was a median follow-up of 93 months (9-140 months). At 7-year follow-up, the cause-specific survival was 96.4% (confidence interval (CI) 95: 89.8.6-100%), the metastasis-free survival rate was 92.4% (CI 95: 82.8-100%) and the loco-regional control rate was 95.8% (CI 95: 88.2-100%)., Conclusions: This long-term follow-up retrospective study demonstrated acceptable local control and good outcome in elderly patients treated by exclusive HFRT for early breast cancer. However, large-scale prospective randomised trials are needed to confirm these results., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
16. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.
- Author
-
Letouzé E, Allory Y, Bollet MA, Radvanyi F, and Guyon F
- Subjects
- Algorithms, Chromosome Breakage, Clone Cells, Computer Simulation, Databases, Genetic, Disease Progression, Humans, Neoplasm Metastasis genetics, Neoplasms pathology, DNA Copy Number Variations genetics, Neoplasms genetics, Precancerous Conditions genetics
- Abstract
We present a computational method, TuMult, for reconstructing the sequence of copy number changes driving carcinogenesis, based on the analysis of several tumor samples from the same patient. We demonstrate the reliability of the method with simulated data, and describe applications to three different cancers, showing that TuMult is a valuable tool for the establishment of clonal relationships between tumor samples and the identification of chromosome aberrations occurring at crucial steps in cancer progression.
- Published
- 2010
- Full Text
- View/download PDF
17. Delayed reaction after adjuvant whole breast radiotherapy at the dose of 42.9 Gy in 13 fractions over 5 weeks: the need for rapid post irradiation clinical assessment and who are the patients at risk?
- Author
-
Kirova YM, Botti M, Campana F, Dendale R, Zervoudis S, Kyrias G, Bollet MA, and Fourquet A
- Subjects
- Dose Fractionation, Radiation, Female, Humans, Prognosis, Skin Diseases diagnosis, Skin Diseases etiology, Breast Neoplasms complications, Breast Neoplasms radiotherapy, Radiation Injuries diagnosis, Radiation Injuries etiology, Radiotherapy, Adjuvant adverse effects
- Published
- 2009
18. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
- Author
-
De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, and Fourquet A
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Middle Aged, Prognosis, Breast Neoplasms metabolism, Neoplasm Metastasis, Plasminogen Activator Inhibitor 1 metabolism, Urokinase-Type Plasminogen Activator metabolism
- Abstract
Unlabelled: This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients., Patients and Methods: Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected., Results: Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence., Conclusion: This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.
- Published
- 2009
19. Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
- Author
-
Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, Degeorges A, Sigal-Zafrani B, Almouzni G, Cottu P, Salmon R, Servant N, Fourquet A, and de Cremoux P
- Subjects
- Adult, Age Factors, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma drug therapy, Carcinoma genetics, Carcinoma radiotherapy, Carcinoma surgery, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Genetic Association Studies, Humans, Mastectomy, Segmental, Neoplasm Recurrence, Local epidemiology, Neoplasms, Hormone-Dependent drug therapy, Neoplasms, Hormone-Dependent genetics, Neoplasms, Hormone-Dependent radiotherapy, Neoplasms, Hormone-Dependent surgery, Premenopause, Prognosis, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction genetics, Young Adult, Aromatase analysis, Biomarkers, Tumor analysis, Breast Neoplasms enzymology, Carcinoma enzymology, Estrogens physiology, Neoplasm Proteins analysis, Neoplasm Recurrence, Local genetics, Neoplasms, Hormone-Dependent enzymology
- Abstract
Introduction: We sought to determine whether the levels of expression of 17 candidate genes were associated with locoregional control after breast-conserving treatments of early-stage breast cancers in young, premenopausal women., Methods: Gene expression was measured by using RT-PCR in the breast tumors of a series of 53 young (younger than 40 years), premenopausal patients. All treatments consisted of primary breast-conserving surgery followed by whole-breast radiotherapy (+/- regional lymph nodes) with or without systemic treatments (chemotherapy +/- hormone therapy). The median follow-up was 10 years., Results: The 10-year locoregional control rate was 70% (95% CI, 57% to 87%). In univariate analysis, no clinical/pathologic prognostic factors were found to be significantly associated with decreased locoregional control. Expression of three genes was found to be significantly associated with an increased locoregional recurrence rate: low estrogen-receptor beta, low aromatase, and high GATA3. Two others were associated with only a trend (P < 0.10): low HER1 and SKP2. In multivariate analysis, only the absence of aromatase was significantly associated with an increased locoregional recurrence rate (P = 0.003; relative risk = 0.49; 95% CI 0.29 to 0.82)., Conclusions: Recent data give credit to the fact that breast cancer in young women is a distinct biologic entity driven by special oncogenic pathways. Our results highlight the role of estrogen-signaling pathways (mainly CYP19/aromatase, GATA3, and ER-beta) in the risk of locoregional recurrence of breast cancer in young women. Confirmation in larger prospective studies is needed.
- Published
- 2009
- Full Text
- View/download PDF
20. The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?
- Author
-
Bauduceau O, Bollet MA, Pons P, Kirova YM, Fayolle M, Zervoudis S, and Campana F
- Subjects
- Adult, Aged, Computer Simulation, Female, Heart diagnostic imaging, Heart radiation effects, Humans, Middle Aged, Postoperative Period, Prospective Studies, Radiotherapy Dosage, Breast Neoplasms diagnostic imaging, Breast Neoplasms radiotherapy, Radiometry methods, Radiotherapy Planning, Computer-Assisted methods, Tomography, X-Ray Computed methods
- Abstract
Purpose: To compare, in terms of ballistics and dosimetry, a conventional and a virtual simulation in 14 patients without changing the set-up., Patients and Methods: 14 women with breast cancer were treated with postoperative radiotherapy from October 2003 to November 2004. Whole breast irradiation alone was indicated (50 Gy at International Committee on Radiation Units [ICRU] point in 25 fractions over 5 weeks) with, in some cases, an additional boost of 16 Gy to the tumor bed--that was not taken into account in this study. After CT scan, tangential fields were conventionally simulated using a Mecaserto Phebus-type simulator-CT scan. The planning target volume (PTV) was the clinical target volume (CTV) expanded with an additional margin of 1 cm in all directions but towards the skin. Both the lungs and the heart were delineated as organs at risk. Dosimetries were computed for the two beams arrangements i.e. 2D conventional and 3D virtual., Results: The mean age of 14 women was 51.4 years (range 26-65). Laterality was the left breast for 6 patients and the right for 8. Few differences were noticeable in terms of gantry angles. The 3D medial fields were more medial with a mean of 8 mm (range 0-15). The 3D lateral fields were more posterior with a mean difference of 8 mm (range 0-25). The dosimetry analysis showed that, with regard to conventional simulations, at least 95% of the CTV received in all cases > 95% of the prescribed dose. However, in 8 out of 14 patients (57%), 15% of the PTV received < 95% of the prescribed dose. The ICRU 50 quality criterion that at least 95% of the PTV (PTV(95%)) should receive at least 95% of the prescribed dose was never met with conventional simulation. In the case of virtual simulation, the ballistics of the treatment were designed to meet the ICRU quality criterion and thus the PTV95% was higher here than with the conventional simulation by a mean of 17.6% +/- 9.7%. The percentage of CTV receiving a dose higher than 107% of the prescribed dose was 21.3% +/- 12% with conventional and 24% +/- 11% with virtual simulation., Conclusion: The high incidence of breast cancer, the essential role of radiotherapy in its treatment and the potential ensuing toxicity explain why so many studies are devoted to the improvements brought to the techniques of this treatment. The virtual planning of the treatment, however, comes up against many difficulties. The countering of the CTV is complex and necessitates a combination of clinical examination and imagery. The choice of margins around the CTV has not been standardised and is largely dependent both on the equipment used and the quality control methods.
- Published
- 2008
21. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.
- Author
-
Bollet MA, Savignoni A, Pierga JY, Lae M, Fourchotte V, Kirova YM, Dendale R, Campana F, Sigal-Zafrani B, Salmon R, Fourquet A, and Vincent-Salomon A
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Invasiveness, Prognosis, Radiotherapy, Adjuvant, Survival Rate, Breast Neoplasms therapy, Carcinoma, Ductal, Breast therapy, Carcinoma, Lobular therapy, Mastectomy, Segmental, Neoadjuvant Therapy
- Abstract
The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery. This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy. Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation (surgery and/or radiotherapy) or mastectomy. Median follow-up was 10 years. Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis. Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P=0.07), due, in part, to the use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients. The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.
- Published
- 2008
- Full Text
- View/download PDF
22. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.
- Author
-
Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, De Rycke Y, Savignoni A, Rigaill G, Hupé P, Fourquet A, Sigal-Zafrani B, Barillot E, and Thiery JP
- Subjects
- Adult, Breast Neoplasms diagnosis, Breast Neoplasms pathology, Carcinoma, Ductal, Breast genetics, Carcinoma, Lobular genetics, Diagnosis, Differential, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local pathology, Neoplasms, Second Primary diagnosis, Predictive Value of Tests, Prognosis, Research Design, Breast Neoplasms genetics, DNA Breaks, DNA, Neoplasm, Neoplasm Recurrence, Local genetics, Neoplasms, Second Primary genetics
- Abstract
Background: To distinguish new primary breast cancers from true recurrences, pangenomic analyses of DNA copy number alterations (CNAs) using single-nucleotide polymorphism arrays have proven useful., Methods: The pangenomic profiles of 22 pairs of primary breast carcinoma (ductal or lobular) and ipsilateral breast cancers from the same patients were analyzed. Hierarchical clustering was performed using CNAs and DNA breakpoint information. A partial identity score developed using DNA breakpoint information was used to quantify partial identities between two tumors. The nature of ipsilateral breast cancers (true recurrence vs new primary tumor) as defined using the clustering methods and the partial identity score was compared with that based on clinical characteristics. Metastasis-free survival was compared among patients with primary tumors and true recurrences as defined using the partial identity score and by clinical characteristics. All statistical tests were two-sided., Results: All methods agreed on the nature of ipsilateral breast cancers for 14 pairs of samples. For five pairs, the clinical definition disagreed with both clustering methods. For three pairs, the two clustering methods were discordant and the one using DNA breakpoints agreed with the clinical definition. The partial identity score confirmed the nature of ipsilateral breast cancers as defined by clustering of DNA breakpoints in 21 of 22 pairs. The difference in metastasis-free survival of patients with new primary tumors and those with true recurrences was not statistically significant when tumors were defined based on clinical and histologic characteristics (5-year metastasis-free survival: 76%, 95% confidence interval [CI] = 52% to 100% for new primary tumors and 38%, 95% CI = 17% to 83% for true recurrences; P = .18; new primary tumor vs true recurrence, hazard ratio = 2.8, 95% CI = 0.6 to 13.7), but the difference was statistically significant when tumors were defined using the partial identity score (5-year metastasis-free survival: 100% for new primary tumors and 29%, 95% CI = 11% to 78% for true recurrences; P = .01)., Conclusions: DNA breakpoint information more often agreed with the clinical determination than CNAs in this population. The partial identity score, which was calculated based on DNA breakpoints, allows statistical discrimination between new primary tumors and true recurrences that could outperform the clinical determination in terms of prognosis.
- Published
- 2008
- Full Text
- View/download PDF
23. Are ipsilateral breast tumour invasive recurrences in young (< or =40 years) women more aggressive than their primary tumours?
- Author
-
Sigal-Zafrani B, Bollet MA, Antoni G, Savignoni A, Vincent-Salomon A, Pierga JY, Salmon R, Sastre-Garau X, and Fourquet A
- Subjects
- Adult, Age Factors, Breast Neoplasms metabolism, Breast Neoplasms mortality, Female, Functional Laterality, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local mortality, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Breast Neoplasms pathology, Neoplasm Recurrence, Local pathology
- Abstract
The characteristics of ipsilateral breast tumour recurrences (IBTRs) relative to those of their primary tumours (PTs) remain scarcely studied. Of 70 young (< or =40 years) premenopausal women with IBTRs, we studied a series of 63 with paired histological data. Median follow-up since IBTR was 10 years. Rates of histological types, grades or hormonal receptors were not significantly different in PTs and in IBTRs. The concordance between IBTRs and their PTs was good for histological types. IBTRs with conserved histological types tended to occur more locally, but not significantly sooner than others. These IBTRs had good concordance for hormone receptors. In discordant cases there were as many losses as appearances of the receptors. The concordance was weak for grades, with equivalent numbers of IBTRs graded lower as higher than their PTs. The 10-year overall survival rate was 70%. Neither the conservation of histological type, location, nor of the two combined were associated with deaths. Early (<2 years) IBTRs, tended to be associated with poorer survival (HR=2.24 (0.92-5.41); P=0.08). IBTRs did not display features of higher aggressiveness than PTs. Neither clinical nor histological definition of a true recurrence could be established other than the conservation of the histological type.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.